Independent Grant Agreement
This agreement is between the grant recipient and Innovative Research, Inc. that, when signed by both parties, is effective as of the date signed.
The grant recipient has designed, and intends to conduct, independent research in accordance with the grant application submitted to Innovative Research, Inc. prior to March 31, 2020 (UPDATED: The application deadline has been extended to May 15, 2020). Innovative Research, Inc. wishes to provide support for this research in the amount of $10,000 issued as $7,500 in unrestricted funds to the affiliated institution and a further $2,500 as a purchase credit to the affiliated institution toward Innovative Research products and services in support of the grant recipient's research as outlined in the grant application. The purchase credit is non-refundable and non-transferable, expires two calendar years from date of issue, and cannot be used in conjunction with any other discounts or offers.
The grant recipient agrees that their research will be conducted in accordance with all applicable laws and regulations and will conform to all applicable standards and guidelines. The grant recipient is solely responsible for conducting the research and will ensure meaningful disclosure to all research participants of financial support of program, including all potential conflicts between recipient and industry. The grant recipient agrees to use unrestricted funds and purchase credit solely in support of their research as represented on the grant application submitted to Innovative Research, Inc.
The grant recipient agrees to the use of their names and likenesses in publicity without notice or any additional compensation, except where prohibited by law. Recipient acknowledges that Innovative Research, Inc. has the right to publicize and broadcast their name, institution, likeness, and fact that they won, and all matters incidental thereto. These activities may include and are not limited to the following: Featuring on the Innovative Research Inc. website/blog, associated press release(s), and email announcements.
The grant recipient acknowledges that any and all activities under this agreement will not be in a restricted market or involve individuals ordinarily in a restricted market or include companies, organizations, or governmental entities from or located in a restricted market.
The grant recipient represents and warrants that it is licensed, registered, or qualified under local law, regulation, policy, and administrative requirements to perform this research and to the extent required by law, has obtained all licenses, consent, authorizations, approvals, and releases necessary to perform the research and to receive the funding as outlined above. The grant recipient represents that conducting the research and receiving the funding is not inconsistent with any other obligations of the grant recipient or any individual or institution affiliated with the grant recipient.
This agreement represents the entire understanding between the parties relating to the subject matter. This agreement supersedes all previous agreements between both parties, both verbal and written, relating to the research and funding except for any obligations that, by their terms, survive independent of this agreement. The grant recipient acknowledges and agrees that they are authorized to solicit and receive funding for this research on behalf of their institution and/or department.
Your source for all things biotech
Stay informed with our expert insights, industry news, and groundbreaking discoveries.
Physicians, patients should be aware of the potential benefits, risks associated with biologic treatments for osteoarthritis
Biologics may lack the efficacy and safety of traditional orthopaedic treatments. ROSEMONT, Ill., Dec. 20, 2017 /PRNewswire-USNewswire/ -- The American...
Human Serum Difference in Biological Research
Innovations are happening all around us and the progressive track of technology has enabled us to do so much that...
Delivering Biologics in Prefilled Syringes
Siliconization is a key process step in the manufacturing of prefilled syringe systems. Biologics are fast becoming the driving force...
World's first Biological House is built from farming waste
So far as sustainable construction materials go, tomato stems and seaweed would seem to belong at the weaker end of...
Factors XI and XII as Targets for New Anticoagulants
Compared with vitamin K antagonists, the direct oral anticoagulants (DOACs) are simpler to administer and are associated with less intracranial...